Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
EBITDA Over Time
Trending higher, above historical average, structural decline.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$-20.87M
↑ 43% above average
Average (9y)
$-36.41M
Historical baseline
Range
High:$-20.87M
Low:$-59.48M
CAGR
-11.0%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | $-20.87M | +13.2% |
| 2023 | $-24.04M | -10.3% |
| 2022 | $-21.79M | +54.9% |
| 2021 | $-48.34M | -98.0% |
| 2020 | $-24.41M | +32.0% |
| 2019 | $-35.88M | +4.9% |
| 2018 | $-37.72M | -1.0% |
| 2017 | $-37.36M | +31.1% |
| 2016 | $-54.21M | +8.9% |
| 2015 | $-59.48M | - |